Submit or Track your Manuscript LOG-IN

Efficacy of Danshen (Salvia miltiorrhiza) Dripping Pills for Prevention of Acute Mountain Sickness: A Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy of Danshen (Salvia miltiorrhiza) Dripping Pills for Prevention of Acute Mountain Sickness: A Randomized, Double-Blind, Placebo-Controlled Trial

Kui Li1, Lijun Li1, Jialun Fu2, Yi He2, Zhaohui Song2, Shuiping Zhou2Luobu Gesang1* and Rui Liu2*

1Tibet Autonomous Region People’s Hospital, Tibet Institute of High Altitude Medicine, Lhasa, China
2Tasly Pharmaceutical Group Company Limited, Tianjin, China


*      Corresponding author: liuruitj2008@126.com; gesang5354@sina.com

ABSTRACT

A randomized, double-blind, placebo-controlled trial was conducted to investigate the efficacy of prophylaxis by administering compound Danshen dripping pills (CDDPs) on acute mountain sickness (AMS). To this end, a total number of 58 healthy low-altitude inhabitants residing in Beijing were randomized to two treatment sequences, receiving either 270mg CDDPs or placebo during an 11-day trip in Tibet, China, at an altitude of more than 3000 m. The Lake Louise Scoring System (LLSS) was also utilized to access AMS incidence and severity, twice a day, during the research period. AMS was further diagnosed when headaches and LLSS≥ 3 were present. A total of 54 subjects completed the study and no significant difference was observed in the number of individuals with AMS between the groups. However, during the whole observation period, the LLSS values for comprehensive AMS symptoms in the group receiving CDDPs indicated lower occurrence than those in the placebo (CON) group. It is noteworthy that, on day 3 (arrival at Lhasa, altitude 3658 m), AMS symptoms (LLSS=3.79) in the CON group had clearly aggravated (P=0.0475) in contrast to those in the group with administration of CDDPs (LLSS=2.31). Besides, arterial oxygen saturation (SaO2) value for those taking CDDPs was significantly higher than that in the CON group (87.86% vs. 85.72%, P=0.0388) on day 10. These preliminary findings suggested that CDDPs might be regarded as an effective prophylaxis for AMS to a certain extent without any specific adverse effects, relieving clinical manifestations of AMS, especially after rapid ascents (Clinical Trial Registry Number: NCT03270787).
 

To share on other social networks, click on P-share. What are these?

Pakistan Journal of Zoology

December

Vol. 52, Iss. 6, Pages 2027-2426

Featuring

Click here for more

Subscribe Today

Receive free updates on new articles, opportunities and benefits


Subscribe Unsubscribe